Kham M Trinh

US Patent:

20020068066, Jun 6, 2002

Filed:

Jun 15, 2001

Appl. No.:

09/881823

Inventors:

Wenyuan Shi - Los Angeles CA, US
Sherie Morrison - Los Angeles CA, US
Kham Trinh - Alhambra CA, US
Letitia Wims - Culver City CA, US
Li Chen - Los Angeles CA, US
Maxwell Anderson - Seattle WA, US

International Classification:

A61K039/09

US Classification:

424/185100, 424/244100

Abstract:

Dental caries in man may be prevented or treated by oral ingestion of human or humanized murine monoclonal IgG and IgM antibodies that bind to surface antigens of cariogenic organisms, such as . The genetically engineered monoclonal antibodies engage the effector apparatus of the human immune system when they bind to cariogenic organisms, resulting in their destruction. In a preferred embodiment, monoclonal antibodies to cariogenic organisms are produced by edible plants, including fruits and vegetables, transformed by DNA sequences that code on expression for the desired antibodies. The antibodies are applied by eating the plants.

US Patent:

20030143234, Jul 31, 2003

Filed:

Feb 14, 2002

Appl. No.:

10/077624

Inventors:

Wenyuan Shi - Los Angeles CA, US
Sherie Morrison - Los Angeles CA, US
Kham Trinh - Alhambra CA, US
Letitia Wims - Culver City CA, US
Li Chen - Los Angeles CA, US
Maxwell Anderson - Seattle WA, US
Fengxia Qi - Harbor City CA, US

International Classification:

A61K039/40
C07K016/46

US Classification:

424/178100, 530/391100

Abstract:

The present invention is based on the discovery of a composition that provides targeted anti-microbial effect. Specifically the composition contains a targeting moiety which recognizes a target microbial organism and an anti-microbial peptide moiety which has anti-microbial activity. In addition, the present invention provides methods of treating a microbial infection, e.g., on mucosal surfaces by using the compositions provided by the present invention.

US Patent:

20040052814, Mar 18, 2004

Filed:

Jul 19, 2001

Appl. No.:

09/910358

Inventors:

Wenyuan Shi - Los Angeles CA, US
Sherie Morrison - Los Angeles CA, US
Kham Trinh - Alhambra CA, US
Letitia Wims - Culver City CA, US
Li Chen - Los Angeles CA, US
Maxwell Anderson - Seattle WA, US

International Classification:

A61K039/02
A61K039/002
C07K014/44
C07K014/195
C07K014/39
C07K014/375

US Classification:

424/190100, 424/191100, 530/350000

Abstract:

Microbial infection may be treated by administration of a fusion protein comprising one or more recognition sequences and at least one antimicrobial peptide. In preferred embodiments, a linker peptide connects the recognition sequence and one or more antimicrobial peptides. The recognition sequence may be an immunoglobulin molecule, or fragment thereof, that specifically binds to a target antigen present on a pathogen. The recognition sequence may also be a non-immunological polypeptide, providing that the polypeptide binds specifically to a particular ligand. In presently preferred embodiments the recognition sequence is monoclonal antibody that binds specifically to and the antimicrobial peptides are derivatives of histatin.

US Patent:

20110165122, Jul 7, 2011

Filed:

Nov 10, 2010

Appl. No.:

12/943757

Inventors:

Arash Shahangian - Los Angeles CA, US
Genhong Cheng - Calabassas CA, US
Lucy S. Cheng - Calabassas CA, US
Kham Moc Trinh - Alhambra CA, US
Paul W. Dempsey - Studio City CA, US
Beichu Guo - Arcadia CA, US
Sherie L. Morrison - Los Angeles CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 38/21
A61K 39/395
A61P 31/12
A61P 37/02
A61P 11/06
A61P 3/10
A61P 37/08
A61P 19/02

US Classification:

424 856, 4241341, 424 857, 424 854

Abstract:

Compounds compositions and methods of modulating the immune response are provided. The method uses fusion proteins of a cytokine and an antibody to potentiate the action of the cytokine.

US Patent:

62845365, Sep 4, 2001

Filed:

Apr 20, 1999

Appl. No.:

9/295283

Inventors:

Sherie L. Morrison - Los Angeles CA
Koteswara R. Chintalacharuvu - Los Angeles CA
Esther Mikyung Yoo - Thousand Oaks CA
Kham M. Trinh - Monterey Park CA
M. Josefina Coloma - Santa Monica CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C12N 506
C12Q 170
G01N 3353
A61K 39395
C12P 2108

US Classification:

435328

Abstract:

Disclosed are modified immunoglobulin (Ig) molecules, a method of producing modified Ig molecules, and methods for treatment and prevention of infectious diseases using modified Ig molecules. In one embodiment, the modified Ig molecule comprises a C. sub. H 3 domain of an IgA molecule (. alpha. C. sub. H 3). The combination of an. alpha. C. sub. H 3 with other domains selected from one or more nonIgA Ig molecules provides an Ig molecule that has the capacity to bind J chain and/or secretory component (SC) together with features of a nonIgA molecule. In another embodiment, the modified Ig molecule comprises a C. sub. H 1 and/or a C. sub. H 2 domain of an IgA molecule. The combination of an. alpha. C. sub. H 1 and/or C. sub. H 2 domain with other domains selected from one or more nonIgA Ig molecules provides an Ig molecule that has the capacity to form higher polymers (trimers, tetramers, pentamers, etc.

US Patent:

20210087249, Mar 25, 2021

Filed:

Mar 18, 2019

Appl. No.:

15/733623

Inventors:

- Oakland CA, US
Reiko King - Los Angeles CA, US
Patricia Young - Los Angeles CA, US
Alex Vasuthasawat - Los Angeles CA, US
Kham M. Trinh - Alhambra CA, US
Sherie Leaver Morrison - Los Angeles CA, US

International Classification:

C07K 14/56
A61P 35/00
C07K 16/28
A61K 35/17
A61K 39/395
A61K 38/21

Abstract:

In various embodiments methods are provided that involve the use of antibody-interferon (Ab-IFN) fusion proteins to boost the cancer-fighting capacity of adoptive T cell therapies (ACT), including any T cells that are manipulated and grown outside the body, then returned to the patient with the goal of having the infused T cells home to sites of tumor and destroy the cancer in an immunologic attack. Illustrative, but non-limiting, adoptive T cell therapies include chimeric antigen receptor (CAR) T cells, tumor-infiltrating lymphocytes (TILs), virus-specific T cells, and T cell receptor transgenic T cells.

US Patent:

20200331966, Oct 22, 2020

Filed:

Apr 15, 2020

Appl. No.:

16/849889

Inventors:

- Los Angeles CA, US
Sherie MORRISON - Los Angeles CA, US
Alex VASUTHASAWAT - Los Angeles CA, US
Kham TRINH - Porter Ranch CA, US
George AYOUB - Los Angeles CA, US

Assignee:

Qwixel Therapeutics - Los Angeles CA

International Classification:

C07K 7/08
A61K 47/65
A61P 35/00

Abstract:

Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.

US Patent:

20160115242, Apr 28, 2016

Filed:

May 29, 2014

Appl. No.:

14/893912

Inventors:

- Oakland CA, US
John M. Timmerman - Los Angeles CA, US
Kham M. Trinh - Alhambra CA, US

International Classification:

C07K 16/30
C07K 14/565
A61N 5/10
A61K 38/21
A61K 45/06
A61K 39/395
C07K 14/56
C07K 14/57

Abstract:

In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-α) or to a mutant interferon alpha or to an interferon beta (IFN-β) or to a mutant interferon beta, or to an interferon gamma (IFN-γ) or to a mutant interferon gamma.